Q1 2022 Results
Company overview
CRM
Financial performance
Immunology
AdakveoⓇ
Financial review
Neuroscience
-
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
P-selectin inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03814746 STAND (CSEG101A2301)
Prevention of Vaso-Occlusive Crises (VOC) in patients with Sickle Cell Disease
(SCD)
Phase 3
240
Rate of VOC events leading to healthcare visit
Crizanlizumab 5.0 mg/kg
Crizanlizumab 7.5 mg/kg
Placebo
Adolescent and adult SCD patients (12 years and older)
Target Patients
Read-out Milestone(s)
2022
Publication
TBD
102 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation